SODIUM IODIDE I

Sodium Iodide I Adverse Events Reported to the FDA Over Time

How are Sodium Iodide I adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Sodium Iodide I, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Sodium Iodide I is flagged as the suspect drug causing the adverse event.

Most Common Sodium Iodide I Adverse Events Reported to the FDA

What are the most common Sodium Iodide I adverse events reported to the FDA?

Hypothyroidism	319 (28.87%)
Treatment Failure	37 (3.35%)
Acute Myeloid Leukaemia	27 (2.44%)
Abortion Spontaneous	21 (1.9%)
Hyperparathyroidism	21 (1.9%)
Myelodysplastic Syndrome	21 (1.9%)
Thyroid Cancer	21 (1.9%)
Hyperthyroidism	18 (1.63%)
Parathyroid Tumour Benign	18 (1.63%)
Breast Cancer	16 (1.45%)
Metastases To Lymph Nodes	14 (1.27%)
	Show More
Sialoadenitis	14 (1.27%)
Hypocalcaemia	13 (1.18%)
Neoplasm Malignant	13 (1.18%)
Drug Exposure During Pregnancy	12 (1.09%)
Colon Cancer	10 (.9%)
Drug Exposure Before Pregnancy	10 (.9%)
Dyspnoea	10 (.9%)
Local Swelling	8 (.72%)
Pulmonary Fibrosis	8 (.72%)
Congenital Hypothyroidism	7 (.63%)
Dacryostenosis Acquired	7 (.63%)
Drug Ineffective	7 (.63%)
Endocrine Ophthalmopathy	7 (.63%)
Gastric Cancer	7 (.63%)
Gingival Bleeding	7 (.63%)
Malignant Urinary Tract Neoplasm	7 (.63%)
Acute Promyelocytic Leukaemia	6 (.54%)
Premature Baby	6 (.54%)
Tongue Discolouration	6 (.54%)
Chronic Myeloid Leukaemia	5 (.45%)
Cyanosis	5 (.45%)
Intra-uterine Death	5 (.45%)
Musculoskeletal Discomfort	5 (.45%)
Parathyroid Gland Enlargement	5 (.45%)
Parathyroid Tumour	5 (.45%)
Parotid Gland Enlargement	5 (.45%)
Radiation Pneumonitis	5 (.45%)
Anaemia	4 (.36%)
Cerebellar Tumour	4 (.36%)
Diarrhoea	4 (.36%)
Fatigue	4 (.36%)
Hyperparathyroidism Primary	4 (.36%)
Hypoaesthesia	4 (.36%)
Hypoparathyroidism	4 (.36%)
Metastases To Lung	4 (.36%)
Psychotic Disorder	4 (.36%)
Stillbirth	4 (.36%)
Thrombocytopenia	4 (.36%)
Abdominal Pain	3 (.27%)
Acute Respiratory Distress Syndrome	3 (.27%)
Ageusia	3 (.27%)
Arthralgia	3 (.27%)
Autoimmune Thyroiditis	3 (.27%)
Blood Thyroid Stimulating Hormone I...	3 (.27%)
Disease Progression	3 (.27%)
Dizziness	3 (.27%)
Drug Toxicity	3 (.27%)
Dysphonia	3 (.27%)
Eye Swelling	3 (.27%)
Headache	3 (.27%)
Hypertension	3 (.27%)
Hyponatraemia	3 (.27%)
Nausea	3 (.27%)
Prothrombin Time Prolonged	3 (.27%)
Rectal Cancer	3 (.27%)
Refractory Anaemia With An Excess O...	3 (.27%)
Refractory Cytopenia With Multiline...	3 (.27%)
Refusal Of Treatment By Patient	3 (.27%)
Sensory Disturbance	3 (.27%)
Sinus Headache	3 (.27%)
Stress Cardiomyopathy	3 (.27%)
Thyroid Neoplasm	3 (.27%)
Thyrotoxic Periodic Paralysis	3 (.27%)
Vomiting	3 (.27%)
Weight Decreased	3 (.27%)
Abortion Induced	2 (.18%)
Apallic Syndrome	2 (.18%)
Astrocytoma	2 (.18%)
Atrial Fibrillation	2 (.18%)
Biopsy Thyroid Gland Abnormal	2 (.18%)
Bone Lesion	2 (.18%)
Bone Marrow Failure	2 (.18%)
Bradycardia	2 (.18%)
Brain Oedema	2 (.18%)
Brain Stem Syndrome	2 (.18%)
Cerebrovascular Accident	2 (.18%)
Chest Pain	2 (.18%)
Cough	2 (.18%)
Decubitus Ulcer	2 (.18%)
Drug Dispensing Error	2 (.18%)
Drug Interaction	2 (.18%)
Dysphagia	2 (.18%)
Ecchymosis	2 (.18%)
Erythema	2 (.18%)
Hepatomegaly	2 (.18%)
Hydrocephalus	2 (.18%)
Hypersensitivity	2 (.18%)
Hypokalaemia	2 (.18%)
Hypophosphataemia	2 (.18%)
Hypoventilation	2 (.18%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Sodium Iodide I, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Sodium Iodide I is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Sodium Iodide I

What are the most common Sodium Iodide I adverse events reported to the FDA?

Thyroid Gland	350 (31.67%)
Leukemias	66 (5.97%)
Therapeutic And Nontherapeutic Effe...	46 (4.16%)
Parathyroid Gland	34 (3.08%)
Abortions And Stillbirth	30 (2.71%)
Endocrine Neoplasms Malignant And U...	29 (2.62%)
Chemical Injury And Poisoning	28 (2.53%)
Metastases	25 (2.26%)
Respiratory	24 (2.17%)
Neurological	23 (2.08%)
Gastrointestinal Neoplasms Malignan...	22 (1.99%)
	Show More
Infections - Pathogen Unspecified	21 (1.9%)
Endocrine Neoplasms Benign	18 (1.63%)
Bone, Calcium, Magnesium And Phosph...	17 (1.54%)
Lower Respiratory Tract Disorders	17 (1.54%)
Miscellaneous And Site Unspecified ...	17 (1.54%)
Breast Neoplasms Malignant And Unsp...	16 (1.45%)
Gastrointestinal Signs	13 (1.18%)
Neonatal And Perinatal Conditions	10 (.9%)
Hematology Investigations	9 (.81%)
Injuries By Physical Agents	9 (.81%)
Anemias Nonhemolytic And Marrow Dep...	8 (.72%)
Anterior Eye Structural Change, Dep...	8 (.72%)
Epidermal And Dermal Conditions	8 (.72%)
Headaches	8 (.72%)
Ocular Structural Change, Deposit A...	8 (.72%)
Renal And Urinary Tract Neoplasms M...	8 (.72%)
Cardiac Disorder Signs	7 (.63%)
Dental And Gingival Conditions	7 (.63%)
Endocrine Disorders Congenital	7 (.63%)
Endocrine Investigations	7 (.63%)
Musculoskeletal And Connective Tiss...	7 (.63%)
Salivary Gland Conditions	7 (.63%)
Cardiac Arrhythmias	6 (.54%)
Central Nervous System Vascular	6 (.54%)
Medication Errors	6 (.54%)
Nervous System Neoplasms Malignant ...	6 (.54%)
Tongue Conditions	6 (.54%)
Electrolyte And Fluid Balance Condi...	5 (.45%)
Gastrointestinal Motility And Defec...	5 (.45%)
Renal Disorders	5 (.45%)
Schizophrenia And Other Psychotic	5 (.45%)
Increased Intracranial Pressure And...	4 (.36%)
Lifestyle Issues	4 (.36%)
Physical Examination Topics	4 (.36%)
Platelet	4 (.36%)
Upper Respiratory Tract Disorders	4 (.36%)
Acid-base	3 (.27%)
Cardiac And Vascular Investigations	3 (.27%)
Coronary Artery	3 (.27%)
Eye	3 (.27%)
Hepatic And Hepatobiliary	3 (.27%)
Joint	3 (.27%)
Maternal Complications Of Labour An...	3 (.27%)
Metabolic, Nutritional And Blood Ga...	3 (.27%)
Oral Soft Tissue Conditions	3 (.27%)
Vascular Hypertensive	3 (.27%)
Allergic Conditions	2 (.18%)
Bacterial Infectious	2 (.18%)
Body Temperature Conditions	2 (.18%)
Bone Disorders	2 (.18%)
Enzyme	2 (.18%)
Hypothalamus And Pituitary Gland	2 (.18%)
Muscle	2 (.18%)
Myocardial	2 (.18%)
Obstetric And Gynecological Therape...	2 (.18%)
Peritoneal And Retroperitoneal Cond...	2 (.18%)
Placental, Amniotic And Cavity Diso...	2 (.18%)
Procedural And Device Related Injur...	2 (.18%)
Psychiatric	2 (.18%)
Skin Vascular Abnormalities	2 (.18%)
Sleep Disorders	2 (.18%)
Vascular	2 (.18%)
White Blood Cell	2 (.18%)
Angiedema And Urticaria	1 (.09%)
Appetite And General Nutritional	1 (.09%)
Arteriosclerosis, Stenosis, Vascula...	1 (.09%)
Bone And Joint Injuries	1 (.09%)
Breast	1 (.09%)
Bronchial Disorders	1 (.09%)
Cardiac And Vascular Disorders Cong...	1 (.09%)
Chromosomal Abnormalities And Abnor...	1 (.09%)
Cranial Nerve Disorders	1 (.09%)
Decreased And Nonspecific Blood Pre...	1 (.09%)
Encephalopathies	1 (.09%)
Fatal Outcomes	1 (.09%)
Gallbladder	1 (.09%)
Gastrointestinal Conditions	1 (.09%)
Gastrointestinal Neoplasms Benign	1 (.09%)
Heart Failures	1 (.09%)
Injuries	1 (.09%)
Maternal Complications Of Pregnancy	1 (.09%)
Menstrual Cycle And Uterine Bleedin...	1 (.09%)
Mental Impairment	1 (.09%)
Miscellaneous And Site Unspecified ...	1 (.09%)
Mood Disorders	1 (.09%)
Musculoskeletal And Connective Tiss...	1 (.09%)
Musculoskeletal And Connective Tiss...	1 (.09%)
Pleural	1 (.09%)
Renal And Urinary Tract Investigati...	1 (.09%)
Reproductive Neoplasms Male Maligna...	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Sodium Iodide I, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Sodium Iodide I is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.